ConductScience.org, home

Paper32165486

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.

Li X and 17 others. Haematologica, 2021. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Papers, record 32165486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32165486

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
PubMed
Journal
Haematologica
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
2.35
iCite
Revised in PubMed
2026-01-27
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li XXinyu
2Su YYongwei
3Hege KKatie
4Madlambayan GGerard
5Edwards HHolly
6Knight TTristan
7Polin LLisa
8Kushner JJuiwanna
9Dzinic SHSijana H
10White KKathryn
11Yang JJay
12Miller RRegan
13Wang GGuan
14Zhao LLijing
15Wang YYue
16Lin HHai
17Taub JWJeffrey W
18Ge YYubin

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Phosphatidylinositol 3-KinasesMajor topic
Animals
Apoptosis
Bridged Bicyclo Compounds, Heterocyclic
Cell Line, Tumor
Humans
Mice
Morpholines
Pyrimidines
Sulfonamides
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA022453NCI NIH HHSUnited StatesP30CA022453PubMed and NIHNIH RePORTER
T32 CA009531NCI NIH HHSUnited StatesT32CA009531PubMed and NIHNIH RePORTER

Download CSV of grants

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130668936A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.Biochem Pharmacol2019https://conductscience.org/library/papers/30668936PubMed
219805519Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.Mol Cell Biol2009https://conductscience.org/library/papers/19805519PubMed
322693356Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res2012https://conductscience.org/library/papers/22693356PubMed
424890832MYC activation is a hallmark of cancer initiation and maintenance.Cold Spring Harb Perspect Med2014https://conductscience.org/library/papers/24890832PubMed
529666304Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.Clin Cancer Res2018https://conductscience.org/library/papers/29666304PubMed
627980108Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.Mol Cancer Ther2017https://conductscience.org/library/papers/27980108PubMed
721901171Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.Genes Cancer2011https://conductscience.org/library/papers/21901171PubMed
830596398Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.J Cell Mol Med2018https://conductscience.org/library/papers/30596398PubMed
918288131Cooperating gene mutations in acute myeloid leukemia: a review of the literature.Leukemia2008https://conductscience.org/library/papers/18288131PubMed
1025308513Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Mol Oncol2015https://conductscience.org/library/papers/25308513PubMed
1120889917Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.Clin Cancer Res2010https://conductscience.org/library/papers/20889917PubMed
1224909171Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.Oncogene2015https://conductscience.org/library/papers/24909171PubMed
1328176818Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.Sci Rep2017https://conductscience.org/library/papers/28176818PubMed
1427103402Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.Clin Cancer Res2016https://conductscience.org/library/papers/27103402PubMed
1530819918Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.Haematologica2019https://conductscience.org/library/papers/30819918PubMed
1625916698Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.Leuk Res2015https://conductscience.org/library/papers/25916698PubMed
1724531733Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.Leukemia2014https://conductscience.org/library/papers/24531733PubMed
1827601886Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature.Patient Prefer Adherence2016https://conductscience.org/library/papers/27601886PubMed
1927166183Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Oncotarget2016https://conductscience.org/library/papers/27166183PubMed
2027049457
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Lancet Oncol2016https://conductscience.org/library/papers/27049457PubMed

See all 32 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
42985246The utility of pyrimidine derivatives in the construction of five-membered non-azole-fused [d]pyrimidines: part III-synthetic strategies and biological applications.RSC Adv2026https://conductscience.org/library/papers/42985246PubMed
42684666Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs2026https://conductscience.org/library/papers/42684666PubMed
42318952PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.Oncol Rep2026https://conductscience.org/library/papers/42318952PubMed
40701845Fimepinostat is a dual inhibitor of tumor and angiogenesis in glioblastoma and synergizes with temozolomide through suppressing MYC.Korean J Physiol Pharmacol2025https://conductscience.org/library/papers/40701845PubMed
40695793Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.Signal Transduct Target Ther2025https://conductscience.org/library/papers/40695793PubMed
40478628Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells.Cancer Res Commun2025https://conductscience.org/library/papers/40478628PubMed
39869284Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer.Invest New Drugs2025https://conductscience.org/library/papers/39869284PubMed
39780285ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/39780285PubMed
39334157NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.J Transl Med2024https://conductscience.org/library/papers/39334157PubMed
39035053The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.Pathol Oncol Res2024https://conductscience.org/library/papers/39035053PubMed
38373594Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.Biochem Pharmacol2024https://conductscience.org/library/papers/38373594PubMed
38266099The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia.Cancer Res2024https://conductscience.org/library/papers/38266099PubMed
38148433Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells.Med Oncol2023https://conductscience.org/library/papers/38148433PubMed
38085423Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.Invest New Drugs2024https://conductscience.org/library/papers/38085423PubMed
36895970A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.Am J Cancer Res2023https://conductscience.org/library/papers/36895970PubMed
36765741Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research.Cancers (Basel)2023https://conductscience.org/library/papers/36765741PubMed
36316313Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia.Cell Death Dis2022https://conductscience.org/library/papers/36316313PubMed
36313732Mechanisms of venetoclax resistance and solutions.Front Oncol2022https://conductscience.org/library/papers/36313732PubMed
36208684Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.Biochem Pharmacol2022https://conductscience.org/library/papers/36208684PubMed
36171897The role of protein acetylation in carcinogenesis and targeted drug discovery.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/36171897PubMed

See all 32 cited byDownload CSV of cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1110018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CHEK11111PubTator's text mininghttps://conductscience.org/library/genes/1111NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
H4C68361PubTator's text mininghttps://conductscience.org/library/genes/8361NCBI Gene
HDAC99734PubTator's text mininghttps://conductscience.org/library/genes/9734NCBI Gene
IL33562PubTator's text mininghttps://conductscience.org/library/genes/3562NCBI Gene
MCL14170PubTator's text mininghttps://conductscience.org/library/genes/4170NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
POTEF728378PubTator's text mininghttps://conductscience.org/library/genes/728378NCBI Gene
RPA26118PubTator's text mininghttps://conductscience.org/library/genes/6118NCBI Gene
RRM16240PubTator's text mininghttps://conductscience.org/library/genes/6240NCBI Gene
WEE17465PubTator's text mininghttps://conductscience.org/library/genes/7465NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32165486

GET https://conductscience.org/api/papers/v1/32165486/references?page=2